TY - JOUR
T1 - The COVID-19 pandemic in children and young people during 2020-2021
T2 - learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment
AU - Rudan, Igor
AU - Adeloye, Davies
AU - Katikireddi, Srinivasa Vittal
AU - Murray, Josie
AU - Simpson, Colin
AU - Shah, Syed Ahmar
AU - Robertson, Chris
AU - Sheikh, Aziz
AU - EAVE II collaboration
N1 - Funding: EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE - The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care.). SVK acknowledges funding from a NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17).
PY - 2021/12/25
Y1 - 2021/12/25
N2 - The initial research questions posed by the scientists faced with SARS-CoV-2 outbreaks were focused on documenting the clinical presentation and the characteristics of the spread of the SARS-CoV-2 virus among CYP [1-3], and the optimal ways to diagnose CYP and treat those in need [1,4]. It quickly became apparent that younger age groups have a considerably milder clinical presentation, but also that they can very rarely develop a considerably more serious Multisystem Inflammatory Syndrome in Children (MISC) [1]. A special interest arose in how best to protect those particularly vulnerable. In this Editorial, we discuss the development of scientific evidence related to those research questions in children and young people during the first two years of the COVID-19 pandemic, based on the information available until December 1st, 2021
AB - The initial research questions posed by the scientists faced with SARS-CoV-2 outbreaks were focused on documenting the clinical presentation and the characteristics of the spread of the SARS-CoV-2 virus among CYP [1-3], and the optimal ways to diagnose CYP and treat those in need [1,4]. It quickly became apparent that younger age groups have a considerably milder clinical presentation, but also that they can very rarely develop a considerably more serious Multisystem Inflammatory Syndrome in Children (MISC) [1]. A special interest arose in how best to protect those particularly vulnerable. In this Editorial, we discuss the development of scientific evidence related to those research questions in children and young people during the first two years of the COVID-19 pandemic, based on the information available until December 1st, 2021
KW - COVID-19
U2 - 10.7189/JOGH.11.01010
DO - 10.7189/JOGH.11.01010
M3 - Editorial
C2 - 35047182
AN - SCOPUS:85123672649
SN - 2047-2978
VL - 11
JO - Journal of Global Health
JF - Journal of Global Health
M1 - 01010
ER -
